Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2014, Article ID 329297, 8 pages
http://dx.doi.org/10.1155/2014/329297
Research Article

Central Portalization Correlates with Fibrosis but Not with Risk Factors for Nonalcoholic Steatohepatitis in Steatotic Chronic Hepatitis C

1Anatomic Pathology, Albany Medical College, 47 New Scotland Avenue, MC81, Albany, NY 12208, USA
2Anatomic Pathology, University of Massachusetts, 1 Innovation Drive, Biotech 3, Worcester, MA 01605, USA
3Anatomic Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9234, USA

Received 6 October 2014; Accepted 10 November 2014; Published 30 November 2014

Academic Editor: Daisuke Morioka

Copyright © 2014 Hwajeong Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Lonardo, P. Loria, L. E. Adinolfi, N. Carulli, and G. Ruggiero, “Hepatitis C and steatosis: a reappraisal,” Journal of Viral Hepatitis, vol. 13, no. 2, pp. 73–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Solis-Herruzo, M. Pérez-Carreras, E. Rivas et al., “Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C,” The American Journal of Gastroenterology, vol. 100, no. 5, pp. 1091–1098, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. M. Younossi, A. J. McCullough, J. P. Ong et al., “Obesity and non-alcoholic fatty liver disease in chronic hepatitis C,” Journal of Clinical Gastroenterology, vol. 38, no. 8, pp. 705–709, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. L. E. Adinolfi, M. Gambardella, A. Andreana, M.-F. Tripodi, R. Utili, and G. Ruggiero, “Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity,” Hepatology, vol. 33, no. 6, pp. 1358–1364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Moriya, H. Fujie, Y. Shintani et al., “The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice,” Nature Medicine, vol. 4, no. 9, pp. 1065–1067, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Hwang and S. D. Lee, “Hepatic steatosis and hepatitis C: still unhappy bedfellows?” Journal of Gastroenterology and Hepatology (Australia), vol. 26, no. 1, pp. 96–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Perlemuter, A. Sabile, P. Letteron et al., “Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis,” FASEB Journal, vol. 16, no. 2, pp. 185–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Rubbia-Brandt, R. Quadri, K. Abid et al., “Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3,” Journal of Hepatology, vol. 33, no. 1, pp. 106–115, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Rubbia-Brandt, G. Leandro, L. Spahr et al., “Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3,” Histopathology, vol. 39, no. 2, pp. 119–124, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Kumar, G. C. Farrell, C. Fung, and J. George, “Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response,” Hepatology, vol. 36, no. 5, pp. 1266–1272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. K. R. Reddy, S. Govindarajan, P. Marcellin et al., “Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin,” Journal of Viral Hepatitis, vol. 15, no. 2, pp. 129–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Castéra, C. Hézode, F. Roudot-Thoraval et al., “Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis,” Gut, vol. 53, no. 3, pp. 420–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Baiocchi, G. Tisone, G. Palmieri et al., “Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation,” Liver Transplantation and Surgery, vol. 4, no. 6, pp. 441–447, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. T. J. S. Cross, M. M. Rashid, P. A. Berry, and P. M. Harrison, “The importance of steatosis in chronic hepatitis C infection and its management: a review,” Hepatology Research, vol. 40, no. 3, pp. 237–247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Ong, Z. M. Younossi, C. Speer, A. Olano, T. Gramlich, and N. Boparai, “Chronic hepatitis C and superimposed nonalcoholic fatty liver disease,” Liver, vol. 21, no. 4, pp. 266–271, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Monto, J. Alonzo, J. J. Watson, C. Grunfeld, and T. L. Wright, “Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol,” Hepatology, vol. 36, no. 3, pp. 729–736, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease,” The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1343–1351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. Hui, A. Sud, G. C. Farrell et al., “Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression,” Gastroenterology, vol. 125, no. 6, pp. 1695–1704, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. L.-K. Chen, S.-J. Hwang, S.-T. Tsai, J.-C. Luo, S.-D. Lee, and F.-Y. Chang, “Glucose intolerance in Chinese patients with chronic hepatitis C,” World Journal of Gastroenterology, vol. 9, no. 3, pp. 505–508, 2003. View at Google Scholar · View at Scopus
  20. M. Sougleri, C. Labropoulou-Karatza, P. Paraskevopoulou, H. Fragopanagou, and T. Alexandrides, “Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with β-thalassaemia major,” European Journal of Gastroenterology and Hepatology, vol. 13, no. 10, pp. 1195–1199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Jaroszewicz and R. Flisiak, “Metabolic syndrome and hepatitis C infection—brothers in arms,” Liver International, vol. 33, no. 8, pp. 1135–1137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-J. Hwang, J.-C. Luo, C.-W. Chu et al., “Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation,” Journal of Gastroenterology and Hepatology, vol. 16, no. 2, pp. 190–195, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Castéra, C. Hézode, F. Roudot-Thoraval et al., “Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies,” Gut, vol. 52, no. 2, pp. 288–292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Poynard, V. Ratziu, J. McHutchison et al., “Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C,” Hepatology, vol. 38, no. 1, pp. 75–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. H. M. Patton, K. Patel, C. Behling et al., “The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients,” Journal of Hepatology, vol. 40, no. 3, pp. 484–490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. T. J. S. Cross, A. Quaglia, J. Nolan, S. Hughes, and P. M. Harrison, “Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?” Journal of Medical Virology, vol. 82, no. 6, pp. 958–964, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Tanaka, S. Uegaki, H. Kurihara et al., “Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C,” World Journal of Gastroenterology, vol. 13, no. 39, pp. 5180–5187, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Ohata, K. Hamasaki, K. Toriyama et al., “Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection,” Cancer, vol. 97, no. 12, pp. 3036–3043, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. D. Clouston, J. R. Jonsson, D. M. Purdie et al., “Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation,” Journal of Hepatology, vol. 34, no. 2, pp. 314–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. I. J. Hickman, A. D. Clouston, G. A. Macdonald et al., “Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C,” Gut, vol. 51, no. 1, pp. 89–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Romero-Gómez, M. Diago, R. J. Andrade et al., “Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin,” Hepatology, vol. 50, no. 6, pp. 1702–1708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. I. A. Hanouneh, A. E. Feldstein, R. Lopez et al., “Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection,” Clinical Gastroenterology and Hepatology, vol. 6, no. 5, pp. 584–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Bondini and Z. M. Younossi, “Non-alcoholic fatty liver disease and hepatitis C infection,” Minerva Gastroenterologica e Dietologica, vol. 52, no. 2, pp. 135–143, 2006. View at Google Scholar · View at Scopus
  34. R. M. Gill, P. Belt, L. Wilson, N. M. Bass, and L. D. Ferrell, “Centrizonal arteries and microvessels in nonalcoholic steatohepatitis,” The American Journal of Surgical Pathology, vol. 35, no. 9, pp. 1400–1404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Ishak, A. Baptista, L. Bianchi et al., “Histological grading and staging of chronic hepatitis,” Journal of Hepatology, vol. 22, no. 6, pp. 696–699, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. D. E. Kleiner, E. M. Brunt, and M. Van Natta, “Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar
  37. A. R. Crawford, X. I.-Z. Lin, and J. M. Crawford, “The normal adult human liver biopsy: a quantitative reference standard,” Hepatology, vol. 28, no. 2, pp. 323–331, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Krings, B. Can, and L. Ferrell, “Aberrant centrizonal features in chronic hepatic venous outflow obstruction: centrilobular mimicry of portal-based disease,” American Journal of Surgical Pathology, vol. 38, no. 2, pp. 205–214, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Calvaruso and A. Craxì, “2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines,” Liver International, vol. 32, no. 1, pp. 2–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, no. 5, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Kukla, A. Gabriel, D. Sabat et al., “Association between liver steatosis and angiogenesis in chronic hepatitis C,” Polish Journal of Pathology, vol. 61, no. 3, pp. 154–160, 2010. View at Google Scholar · View at Scopus
  42. A. Gabriel, M. Kukla, M. Wilk, Ł. Liszka, M. Petelenz, and J. Musialik, “Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage,” Pathology Research and Practice, vol. 205, no. 11, pp. 758–764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Fernández, D. Semela, J. Bruix, I. Colle, M. Pinzani, and J. Bosch, “Angiogenesis in liver disease,” Journal of Hepatology, vol. 50, no. 3, pp. 604–620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Medina, A. G. Arroyo, F. Sánchez-Madrid, and R. Moreno-Otero, “Angiogenesis in chronic inflammatory liver disease,” Hepatology, vol. 39, no. 5, pp. 1185–1195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Aleffi, I. Petrai, C. Bertolani et al., “Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells,” Hepatology, vol. 42, no. 6, pp. 1339–1348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Novo, S. Cannito, E. Zamara et al., “Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells,” American Journal of Pathology, vol. 170, no. 6, pp. 1942–1953, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Ankoma-Sey, M. Matli, K. B. Chang et al., “Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing,” Oncogene, vol. 17, no. 1, pp. 115–121, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Q. Wang, J. M. Luk, K. Ikeda et al., “Regulatory role of vHL/HIF-1α in hypoxia-induced VEGF production in hepatic stellate cells,” Biochemical and Biophysical Research Communications, vol. 317, no. 2, pp. 358–362, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Matsukuma, H. Takeo, T. Kono, Y. Nagata, and K. Sato, “Aberrant cytokeratin 7 expression of centrilobular hepatocytes: a clinicopathological study,” Histopathology, vol. 61, no. 5, pp. 857–862, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. R. K. Pai and J. A. Hart, “Aberrant expression of cytokeratin 7 in perivenular hepatocytes correlates with a cholestatic chemistry profile in patients with heart failure,” Modern Pathology, vol. 23, no. 12, pp. 1650–1656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. V. J. Desmet, “Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. Types of ductular reaction reconsidered,” Virchows Archiv, vol. 458, no. 3, pp. 251–259, 2011. View at Publisher · View at Google Scholar · View at Scopus